Highest-materiality recent filing
Niagen Bioscience Q1 net sales $31.5M (+3% YoY); net income $6.3M up from $5.1M
Gross margin 63.5%; adjusted EBITDA $3.8M vs $4.9M year ago.
Niagen Bioscience reports 30% net sales growth to $129.4M in 2025; net income up 103% to $17.4M
Full year 2025 net sales $129.4M (+30% YoY); net income $17.4M (+103%); adjusted EBITDA $20.4M (+139%).
Niagen Bioscience sells ChromaDex Reference Standards business to LGC in all-cash deal
All-cash sale closed Feb 24, 2026; buyer is VHG Labs, part of LGC Group.
Niagen acquires QUB NR patent portfolio; $1M upfront, annual payments through 2038
One-time ~$1M payment to QUB for accrued royalties through 2024; annual $500K+£35K through 2038.
Net sales $34.0M (+33% YoY); Tru Niagen sales $26.0M (+44% YoY).
Niagen Bioscience raises FY2025 net sales growth guidance to 25%-30% YoY
Full-year 2025 net sales outlook raised to 25%-30% YoY growth from prior 22%-27%.
Niagen Bioscience Q2 net sales up 37% to $31.1M; raises FY2025 guidance to 22%-27% growth
Net sales $31.1M (+37% YoY); net income $3.6M ($0.05 EPS) vs breakeven in Q2 2024.
Niagen subsidiary ChromaDex signs exclusive NRCL supply deal with W.R. Grace through 2029
Exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL); Grace cannot sell to third parties.
Niagen Bioscience Q1 net sales $30.5M (+38% YoY), net income $5.1M, raises FY2025 outlook
Total net sales of $30.5M, up 38% YoY; gross margin 63.4% (+270 bps).
ChromaDex reports record Q4 net sales $29.1M (+37% YoY); first full-year net income $8.6M
Full-year net sales $99.6M (+19% YoY); Tru Niagen sales $76.8M (+10%), Niagen ingredients $19.2M (+82%).
Dartmouth waives ~$3.5M in accrued unpaid royalties, license fees, and maintenance expenses under exclusive license agreements.
ChromaDex posts record Q3: net sales $25.6M (+31% YoY), net income $1.9M
Net sales $25.6M (+31% YoY); gross margin 63.5% (+210 bps).
ChromaDex auditor Marcum resigns effective Oct 31 due to conflict from CBIZ merger
Marcum LLP resigned as independent auditor effective Oct 31, 2024, citing independence concerns from its impending merger with CBIZ Inc.
ChromaDex Q2 net sales up 12% to $22.7M; adjusted EBITDA positive $1.6M
Total net sales $22.7M (+12% YoY); Tru Niagen sales $18.6M (+10% YoY).
ChromaDex CFO Brianna Gerber resigns effective July 12; consulting transition through Aug 12
CFO & CAO Brianna Gerber resigns effective July 12, 2024; company beginning search for replacement.
ChromaDex Q1 net sales $22.2M, net loss narrows to $0.5M; reiterates 16%+ FY growth
Net sales $22.2M (-2% YoY); Tru Niagen sales $17.4M. Gross margin 60.7% (+80 bps).
ChromaDex posts Q4 net income of $0.1M; FY2023 revenue up 16% to $83.6M
Q4 net sales $21.2M (+1% YoY); Tru Niagen sales $17.6M (+9% YoY).
On September 19, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed Ozan Pamir as the Company’s Chief Financial Officer and Principal Accounting Officer, effective as of October 21, 2024
Mr. Pamir will replace James Lee, who is currently serving as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer.
On July 16, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed James Lee, the Company’s current Controller, as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of July 13, 2024.
As previously disclosed, Brianna Gerber resigned from her roles as the Company’s Chief Financial Officer and Principal Accounting Officer effective July 12, 2024.
On June 19, 2024, Brianna Gerber, the Chief Financial Officer and Chief Accounting Officer of ChromaDex Corporation (the “Company”), informed the Company that she will be resigning from her roles with the Company, effective July 12, 2024 (the “Separation Date”).
Max materiality 0.85 · Median 0.65 · Most common event other_material